Observational studyBMC anesthesiology2025
ICG clearance as an indicator of augmented hepatic clearance and subtherapeutic drug concentrations in septic patients.
Observational study in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced Indocyanine Green Clearance Is Associated with Enteral Feeding Intolerance in Septic Patients Without Overt Liver Injury.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo assess indocyanine green (ICG) clearance as a quantitative indicator of augmented hepatic clearance (AHC) in septic patients and to evaluate its impact on subtherapeutic antibiotic concentrations and 28-day mortality.
methodsThis prospective observational study enrolled 93 septic patients admitted to the intensive care unit (ICU), from whom 113 ICG clearance tests were obtained. Patients were stratified into three groups based on ICG retention rate at 15 min (ICG-R15): augmented (AHC, ICG-R15 < 6%), normal (NHC, 6% ≤ ICG-R15 ≤ 12%), and impaired hepatic clearance (IHC, ICG-R15 > 12%). Trough concentrations were measured for the following antibiotics: imipenem/cilastatin, piperacillin/tazobactam, voriconazole, linezolid, vancomycin, cefoperazone/sulbactam, and teicoplanin. Correlations between ICG clearance parameters (ICG-R15 and ICG plasma disappearance rate [PDR] ) and antibiotic concentrations were analyzed. Multivariate logistic regression and ROC analysis were performed to identify independent predictors of subtherapeutic concentrations.
resultsNearly half of the cohort (49.5%, 46/93) presented with AHC. The 28-day mortality rate was highest in the IHC group (48.4%), with no significant difference between the AHC (10.9%) and NHC (12.5%) groups. Trough concentrations of hepatically or partially cleared antibiotics (voriconazole and linezolid) showed strong correlations with ICG-R15 (r = 0.679 and r = 0.626, respectively) and ICG-PDR (r = -0.673 and r = -0.629, respectively; all p < 0.01). No significant correlations were found for renally cleared antibiotics (imipenem, piperacillin). Multivariate analysis identified ICG-PDR as the only independent predictor of subtherapeutic concentrations for hepatically or partially eliminated antibiotics (OR = 0.885, 95% CI: 0.807-0.970, p = 0.009). In ROC analysis, ICG-PDR demonstrated excellent predictive performance for the entire antibiotic cohort (AUC = 0.853, p < 0.001), with a sensitivity of 89.5% and specificity of 72.6% at the optimal cut-off of 20.65%/min. When specifically applied to hepatically cleared antibiotics, it remained a strong predictor (AUC = 0.791, p = 0.003), with a cut-off of 21.55%/min yielding a sensitivity of 81.8% and specificity of 71.1%.
conclusionAHC is a prevalent phenotype in sepsis and identifies a patient subgroup at high risk for subtherapeutic concentrations of hepatically or partially cleared antibiotics. ICG-derived parameters, particularly ICG-PDR, are robust predictors of inadequate drug exposure, supporting the use of dynamic liver function monitoring to optimize antibiotic dosing in septic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.